Cancer combination therapies with artemisinin-type drugs
Cancer combination therapies with artemisinin-type drugs
复制标题
DOI：
10.1016/j.bcp.2017.03.019
复制
发表时间：
2017-09-01
影响因子：
5.8
通讯作者：
Efferth, Thomas
中科院分区：
文献类型：
--
作者：
Efferth, Thomas
[医]黄花蒿是一种中国药用植物，在亚洲和非洲被用作茶或果汁来治疗疟疾。然而，其化学成分青蒿素的生物活性要广泛得多。我们和其他人发现，青蒿素及其衍生物在体外和体内也对肿瘤细胞产生了深远的影响。如果青蒿素类药物将来在临床肿瘤学中常规应用，那么它可能应该作为联合治疗方案的一部分，而不是作为单一疗法。在本综述中，我对青蒿素类药物与不同类型的细胞毒性药物和治疗方式联合使用的协同和累加效应进行了全面概述：（a）标准化学治疗药物，（B）放射疗法和光动力疗法，（c）用于癌症以外的其它适应症的已建立的药物，（d）新的合成化合物，（e）天然产物和天然产物衍生物，（f）治疗性抗体和重组蛋白，和（g）RNA干扰。本文还总结了青蒿素类药物对多药耐药细胞和具有其他耐药现象的肿瘤细胞的作用。由于协同相互作用可能不仅发生在肿瘤细胞中，还考虑了正常细胞中的毒性反应（肝毒性、药物相互作用）。这篇综述总结了截至2016年底20多年来的科学文献。(C)2017爱思唯尔公司All rights reserved.
Artemisia annua L. is a Chinese medicinal plant, which is used throughout Asia and Africa as tea or press juice to treat malaria. The bioactivity of its chemical constituent, artemisinin is, however, much broader. We and others found that artemisinin and its derivatives also exert profound activity against tumor cells in vitro and in vivo. Should artemisinin-type drugs be applied routinely in clinical oncology in the future, then it should probably be as part of combination therapy regimens rather than as monotherapy. In the present review, I give a comprehensive overview on synergistic and additive effects of artemisinin-type drugs in combination with different types of cytotoxic agents and treatment modalities: (a) standard chemotherapeutic drugs, (b) radiotherapy and photodynamic therapy, (c) established drugs for other indications than cancer, (d) novel synthetic compounds, (e) natural products and natural product derivatives, (f) therapeutic antibodies and recombinant proteins, and (g) RNA interference. I also summarize the activity of artemisinin-type drugs towards multidrug-resistant cells and tumor cells with other drug resistance phenomena. As synergistic interactions may not only occur in tumor cells, toxic reactions in normal cells (hepatotoxicity, drug interactions) were also considered. This review summarizes the scientific literature of more than 20 years until the end of 2016. (C) 2017 Elsevier Inc. All rights reserved.